Genome-wide profiling of human papillomavirus DNA integration in liquid-based cytology specimens from a Gabonese female population using HPV capture technology.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 02 2019
Historique:
received: 13 10 2017
accepted: 10 12 2018
entrez: 8 2 2019
pubmed: 8 2 2019
medline: 1 9 2020
Statut: epublish

Résumé

Human papillomavirus (HPV) is recognised as the cause of precancerous and cancerous cervical lesions. Furthermore, in high-grade lesions, HPV is frequently integrated in the host cell genome and associated with the partial or complete loss of the E1 and E2 genes, which regulate the activity of viral oncoproteins E6 and E7. In this study, using a double-capture system followed by high-throughput sequencing, we determined the HPV integration status present in liquid-based cervical smears in an urban Gabonese population. The main inclusion criteria were based on cytological grade and the detection of the HPV16 genotype using molecular assays. The rate of HPV integration in the host genome varied with cytological grade: 85.7% (6/7), 71.4% (5/7), 66.7% (2/3) 60% (3/5) and 30.8% (4/13) for carcinomas, HSIL, ASCH, LSIL and ASCUS, respectively. For high cytological grades (carcinomas and HSIL), genotypes HPV16 and 18 represented 92.9% of the samples (13/14). The integrated form of HPV16 genotype was mainly found in high-grade lesions in 71.4% of samples regardless of cytological grade. Minority genotypes (HPV33, 51, 58 and 59) were found in LSIL samples, except HPV59, which was identified in one HSIL sample. Among all the HPV genotypes identified after double capture, 10 genotypes (HPV30, 35, 39, 44, 45, 53, 56, 59, 74 and 82) were detected only in episomal form. Our study revealed that the degree of HPV integration varies with cervical cytological grade. The integration event might be a potential clinical prognostic biomarker for the prediction of the progression of neoplastic lesions.

Identifiants

pubmed: 30728408
doi: 10.1038/s41598-018-37871-2
pii: 10.1038/s41598-018-37871-2
pmc: PMC6365579
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1504

Références

J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Cancer Res. 1999 Nov 1;59(21):5615-24
pubmed: 10554043
Cancer Res. 2000 Nov 1;60(21):5916-21
pubmed: 11085503
Int J Cancer. 2001 Apr 1;92(1):9-17
pubmed: 11279600
Int J Cancer. 2001 Oct 15;94(2):153-6
pubmed: 11668491
Virus Res. 2002 Nov;89(2):183-90
pubmed: 12445658
J Gen Virol. 1992 Aug;73 ( Pt 8):2059-66
pubmed: 1322962
J Gen Virol. 1992 Sep;73 ( Pt 9):2327-36
pubmed: 1328489
J Pathol. 2004 Jan;202(1):23-33
pubmed: 14694518
Cancer Res. 2004 Jun 1;64(11):3878-84
pubmed: 15172997
J Clin Pathol. 1991 Dec;44(12):990-6
pubmed: 1665153
J Clin Microbiol. 2006 May;44(5):1755-62
pubmed: 16672403
Med Oncol. 2011 Dec;28(4):1411-7
pubmed: 20467918
J Pathol. 2010 Jul;221(3):320-30
pubmed: 20527025
J Mol Diagn. 2011 May;13(3):325-33
pubmed: 21497292
Curr Opin Biotechnol. 2012 Feb;23(1):9-15
pubmed: 22154470
Lancet. 2012 Nov 24;380(9856):1840-50
pubmed: 23079588
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054
pubmed: 23543559
G3 (Bethesda). 2013 Aug 07;3(8):1213-24
pubmed: 23550136
Asian Pac J Cancer Prev. 2013;14(6):3837-41
pubmed: 23886192
Nature. 2013 Aug 8;500(7461):207-11
pubmed: 23925245
Int J Biol Markers. 2014 Mar 24;29(1):e78-85
pubmed: 24170557
Genome Res. 2014 Feb;24(2):185-99
pubmed: 24201445
Nature. 2014 Feb 20;506(7488):371-5
pubmed: 24390348
Int J Gynecol Cancer. 2014 Feb;24(2):329-38
pubmed: 24418928
Br J Cancer. 2014 Feb 18;110(4):1034-44
pubmed: 24423925
BMC Bioinformatics. 2014 Oct 22;15:348
pubmed: 25331652
Nat Genet. 2015 Feb;47(2):158-63
pubmed: 25581428
Int J Cancer. 2015 Aug 15;137(4):776-83
pubmed: 25626421
Br J Cancer. 2015 Jun 9;112(12):1958-65
pubmed: 25973533
Exp Ther Med. 2015 Dec;10(6):2169-2174
pubmed: 26668611
Nat Genet. 2016 Jan;48(1):2-4
pubmed: 26711106
Infect Agent Cancer. 2016 Jan 15;11:2
pubmed: 26779280
Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):1004-5
pubmed: 27009212
Infect Agent Cancer. 2016 Aug 16;11:42
pubmed: 27532014
Infect Agent Cancer. 2016 Sep 07;11(1):50
pubmed: 27610192
Sci Rep. 2016 Oct 19;6:35427
pubmed: 27759101
BMC Genomics. 2016 Nov 2;17(1):851
pubmed: 27806689
J Exp Clin Cancer Res. 2016 Nov 25;35(1):180
pubmed: 27884161
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Virology. 1987 Nov;161(1):259-61
pubmed: 2823467
Open Med (Wars). 2014 Sep 25;10(1):1-7
pubmed: 28352670
Int J Mol Sci. 2017 Sep 22;18(10):null
pubmed: 28937589
NPJ Genom Med. 2016 Mar 16;1:16004
pubmed: 29263809
Int J Cancer. 1997 Feb 20;74(1):50-6
pubmed: 9036869

Auteurs

Andriniaina Andy Nkili-Meyong (AA)

Centre International de Recherches Médicales de Franceville (CIRMF) Department of Zoonosis and Emerging Diseases, Franceville, Gabon.

Pamela Moussavou-Boundzanga (P)

Centre International de Recherches Médicales de Franceville (CIRMF) Department of Zoonosis and Emerging Diseases, Franceville, Gabon.

Ingrid Labouba (I)

Centre International de Recherches Médicales de Franceville (CIRMF) Department of Zoonosis and Emerging Diseases, Franceville, Gabon.

Ismaël Hervé Koumakpayi (IH)

Institut de Cancérologie de Libreville (ICL), Libreville, Gabon.

Emmanuelle Jeannot (E)

Institut Curie, Department of Biopathology, 26 Rue d'Ulm, 75005, Paris, France.

Stéphane Descorps-Declère (S)

Institut Pasteur, Centre de Bioinformatique, Biostatistique et Biologie Intégrative (C3BI), 25 rue du docteur Roux, 75724, Paris, France.

Xavier Sastre-Garau (X)

Institut de Cancérologie de Lorraine (ICL), 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.

Eric M Leroy (EM)

Centre International de Recherches Médicales de Franceville (CIRMF) Department of Zoonosis and Emerging Diseases, Franceville, Gabon.
Institut de Recherches et de Développement (IRD), Maladies Infectieuses et vecteurs: Ecologie, génétique, Evolution et Contrôle (IRD 224 - CNRS 5290 6 UM1- UM2), Montpellier, France.

Ernest Belembaogo (E)

Institut de Cancérologie de Libreville (ICL), Libreville, Gabon.

Nicolas Berthet (N)

Centre International de Recherches Médicales de Franceville (CIRMF) Department of Zoonosis and Emerging Diseases, Franceville, Gabon. nicolas.berthet@pasteur.fr.
Centre National de Recherche Scientifique (CNRS) UMR3569, 25 rue du docteur Roux, 75724, Paris, France. nicolas.berthet@pasteur.fr.
Institut Pasteur, Unité Environnement et risques infectieux, Cellule d'Intervention Biologique d'Urgence, 25 rue du Docteur Roux, 75724, Paris, France. nicolas.berthet@pasteur.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH